Seeking Alpha

Vertex Pharmaceuticals (VRTX -2.3%) and partner Alios BioPharma say they've decided to...

Vertex Pharmaceuticals (VRTX -2.3%) and partner Alios BioPharma say they've decided to discontinue development of their hepatitis C virus drug candidate ALS-2158 due to disappointing results, but plan to begin Phase II testing of ALS-2200, an orally administered HCV drug regimen, by the end of the year. The companies hope to run one Phase II test of the drug in combination with Ribvarin, and a second testing with VRTX's recently approved HCV therapy Incivek.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|